BETHESDA, Md., Nov. 15, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) today announced that it will participate in the annual meeting of the Society of Neuro-Oncology (SNO) to be held at the Hyatt Regency, Orange County, California from November 17-20. SNO is the premier professional society comprising neuro-oncologists from across the U.S. and abroad.
The Company's program will include a presentation on its DCVax®-L cancer vaccine, a breakfast meeting with physicians who are current and potential investigators (i.e., lead participants at clinical trial sites), as well as other medical personnel, in the Company's ongoing Phase II clinical trial in GBM brain cancer, and an exhibit booth for any physicians or attendees interested in learning more about the DCVax results to date and progress moving forward.
The presentation on Saturday, November 19, 2011, will be at the symposium "Current State Of The Art: Vaccine Development In The Treatment of GBM." It will be held at 12 noon in the Grand Ballroom of the Hyatt. Dr. Anthony Maida will review the encouraging prior clinical data for DCVax, and discuss the ongoing 240-patient trial in newly diagnosed GBM, the most lethal form of brain cancer. This Phase II clinical trial is a randomized, double blind, placebo controlled trial currently underway at 19 clinical sites across the US, with further sites in the process of being added.
On Saturday, November 19, 2011 at 8:00 a.m., the Company will host a unique private meeting for current and potential clinical trial site doctors, nurses and other interested medical personnel concerning the Company's ongoing GBM clinical trial. The objective of this meeting will be to update current or pending sites about all aspects of this clinical trial program, as well as answer questions from potential sites that may want to participate in the future. Newly interested parties will be asked to execute a Confidentiality Agreement. Open and active trial sites are listed on the U.S. Government's website, www.clinicaltrials.gov, and on Northwest Bio's website at www.nwbio.com.
Finally, Northwest Bio also will host an exhibit booth in the Hyatt's Exposition Hall for the full duration of the Conference. Information about Northwest Bio, its multiple product candidates for solid tumors, its pipeline of INDs cleared by the FDA for clinical trials in multiple cancers, its prior clinical trial data and other information, including the process for participation in the Company's clinical trials, all will be presented by Company representatives.
Linda Powers, CEO of Northwest Bio, said, "Our clinical and scientific team looks forward to this premier gathering of medical professionals specializing in neuro-oncology, and the opportunity to update these specialists about the exciting progress and prospects of DCVax for GBM brain cancer – a cancer with a very bleak outlook for patients today."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe. The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax for recurrent metastatic ovarian cancer. For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
SOURCE Northwest Biotherapeutics, Inc.